46results about How to "Improve exercise tolerance" patented technology

The present invention relates to the identification of a microRNA, miR-208, that induces the expression of β-myosin heavy chain (β-MHC) and represses fast skeletal muscle contractile protein genes. Inhibition of this function is proposed as a treatment for cardiac fibrosis, hypertrophy and / or heart failure, and augmentation of this function can be used to repress slow fiber genes and activate fast fiber genes in the treatment of musculoskeletal disorders.

The present invention relates to the identification of a microRNA, miR-208, that induces the expression of β-myosin heavy chain (β-MHC) and represses fast skeletal muscle contractile protein genes. Inhibition of this function is proposed as a treatment for cardiac fibrosis, hypertrophy and / or heart failure, and augmentation of this function can be used to repress slow fiber genes and activate fast fiber genes in the treatment of musculoskeletal disorders.

A treatment apparatus including: a bronchoscope including a flexible shaft having working channel; a transbronchial ablation probe configured to extend from a distal end of the working channel and extend thru a wall of a trachea and into tissue outside of the trachea; and a stabilization element mounted to a distal portion of the flexible shaft, wherein the stabilization element is configured to brace the distal portion against the wall of the trachea while the transbronchial ablation probe is extended through the wall of the trachea.

Provided herein are methods for treating pulmonary hypertension. The methods include administering to a subject in need thereof an effective amount of a vasodilator, wherein the vasodilator is administered to the subject via inhalation pro re nata using a portable inhaler. In some embodiments, the vasodilator is a PDE5 inhibitor. Pharmaceutical compositions for pro re nata administration of vasodilators are also described.

Provided is the use of a Salvia Miltiorrhiza composition in preparing drugs for secondary prevention of coronary heart disease, and particularly the use of the Salvia Miltiorrhiza composition in preparing drugs for secondary prevention of stable angina type coronary heart disease and the reduction of serious vascular events.

This document provides methods and materials for modulating afferent nerve signals to treat medical conditions such as CHF, CHF respiration, dyspnea, peripheral vascular disease (e.g., peripheral arterial disease or venous insufficiency), hypertension (e.g., age-associated hypertension, resistant hypertension, or chronic refractory hypertension), COPD, sleep apnea, and chronic forms of lung disease where muscle dysfunction is a part of the disease pathophysiology. For example, methods and materials involved in using electrical and / or chemical techniques to block or reduce afferent nerve signals (e.g., nerve signals of group III and / or IV afferents coming from skeletal muscle and / or the kidneys) are provided.

The invention discloses a wristband watchband with a conductive function, relates to the technical field of smart wristbands, and aims to solve the problem that the watchband is only used for fixing awristband on a wrist and has fewer functions. Key points of the technical scheme are as follows, the watchband comprises a buckle end silica gel watchband and a tongue end silica gel watchband. A buckle is arranged on the buckle end silica gel watchband; a plurality of lock holes are formed in the tongue end silica gel watchband, an electrical stimulation module is arranged in the buckle end silica gel watchband, the electrical stimulation module comprises a signal strip arranged in the length direction of the buckle end silica gel watchband, a circuit board connected with the signal strip and an electrode connected with the circuit board, and the electrode is located at the end, away from the dial plate, of the buckle end silica gel watchband. The signal strip is placed in the buckle endsilica gel watchband, the characteristics of conductivity, waterproofness, stability and the like are achieved, the functionality of the watchband is improved, an electrode is installed at a port ofthe buckle end silica gel watchband, the space of a wristband host is saved, the signal strip embedded in the buckle end silica gel watchband is laid in a snake shape, and the bendable characteristicof the buckle end silica gel watchband is achieved.

Nebivolol has been shown to be beneficial in the treatment of cardiovascular diseases such hypertension, congestive heart failure, arterial stiffness and endothelial dysfunction. The present invention features a pharmaceutical composition comprising nebivolol and at least one other active agent, wherein the at least one other active agent is a cardiovascular agent.

The invention discloses a preparation method of a codfish source function low-bitterness oligopeptide. The method comprises the following steps of (1) pretreatment: performing fishskin and fishbone removal on codfish; then, cleanly cleaning the codfish by distilled water; extruding moisture to obtain codfish meat for use; (2) homogenizing: performing primary homogenizing treatment on the codfish meat obtained in the step (1); mixing the codfish meat subjected to the primary homogenizing treatment and distilled water; then, performing secondary homogenizing to obtain codfish meat paste; (3) enzymolysis: firstly, adding bromelain into the codfish meat paste obtained in the step (2) for primary enzymolysis; then, performing enzyme deactivation; then, adding flavourzyme for secondary enzymolysis; performing enzyme deactivation; (4) centrifugation: performing centrifugation on enzymolysis products in the step (3) for 20 to 30 min at 7000 to 8000rpm; (5) spray drying: taking supernate afterthe centrifugation in the step (4); performing spray drying to obtain a finished product. The preparation method is simple; the preparation conditions are mild and can be easily realized; the bitterness of the prepared oligopeptide is low; the utilization rate is low; better flavor is realized; a good sport fatigue resistant effect is achieved.

The neurosism treating Chinese medicine is prepared with American ginseng, royal jelly, wolfberry fruit, schisandra, melissa powder, propolis, eucommia bark, haw, honey and Dangshen in certain weight proportion. The preparation process includes grinding haw into fine powder, mixing American powder of ginseng, wolfberry fruit, schisandra, eucommia bark and Dangshen, percolating and collecting the percolate, decompression concentration to obtain extractum while recovering alcohol, grinding royal jelly, honey and melissa powder, mixing with haw powder, the extractum and proper amount of dextrin, pelletizing, and drying. The present invention has the advantages of determined and obvious curative effect, and no toxic side effect.

The invention relates to a therapeutic drug for treating arrhythmia, angina and mild and moderate hypertension as well as the preparation method thereof. The therapeutic drug aims to supplement the deficiency of the prior art and provide a sustained-release atenolol dropping pill formulation. The sustained-release atenolol dropping pill is prepared by adding stabilize Vitamin E and a hydrophobic base to the ingredients accepted in the prior art, thereby effectively overcoming the defects in the prior art and guaranteeing no occurrence of an obvious change related to the substance content for the drug during the effective storage period and has the advantages of full release, controllable release time, low frequency of drug taking, long effective hours and high bioavailability simultaneously. The sustained-release atenolol dropping pill is suitable for clinical and family use.

The present invention provides methods for inhibiting Fyn kinase, using 5-3-pyridin-2-amine, 6-3-imidazo[1,2-a] pyrazine, 6-3-imidazo[1,2-b] pyridazine, N-(5-imidazo [2,1-b][1,3,4] thiadiazol-2-yl)-amine, 4-3-1H-pyrazolo[3,4-b] pyridine, and N-(3-imidazo [1,2-b] pyridazin-6-yl) amine compounds and methods of treatment, prevention, inhibition or amelioration of diseases and conditions associated with Fyn kinase using such compounds.

Provided is the use of a Salvia Miltiorrhiza composition in preparing drugs for secondary prevention of coronary heart disease, and particularly the use of the Salvia Miltiorrhiza composition in preparing drugs for secondary prevention of stable angina type coronary heart disease and the reduction of serious vascular events.

The invention discloses a Chinese herbal compound for treating idiopathic pulmonary fibrosis as well as a preparation method and application thereof. The Chinese herbal compound is 'wheat flavor lungnourishing soup', which is prepared from twelve traditional Chinese medicine raw materials such as schisandra chinensis, codonopsis pilosula, radix ophiopogonis, fructus perillae, roasted ephedra herb, aster, pericarpium citri reticulatae, ginger processed pinellia, asarum, roasted radix scutellariae, angelica sinensis and roasted licorice roots. A clinical experiment shows that clinical symptomsof an idiopathic pulmonary fibrosis patient, particularly a patient suffering from deficiency of both vital energy and yin, can be obviously improved, the living quality is improved, and the exercisetolerance is enhanced; the Chinese herbal compound is high in safety, and can reduce the lowering rate of the lung functions to a certain extent.

A use of a poultry crude protein extract for preparing an anti-fatigue composition is provided. The poultry crude protein extract is obtained by extraction of poultry meat at high temperature and high pressure and the removal of fat by oil and water separation, and the poultry crude protein extract includes at least branched-chain amino acid (BCAA), histidine, threonine, lysine, and phenylalanine, wherein anti-fatigue entails increasing muscle glycogen concentration, helping to increase exercise tolerance, helping to increase blood urea nitrogen metabolism, and helping to inhibit lactic acid production.

The present invention relates to one kind of compound hypotensor preparation, and belongs to the field of hypertension treating medicines. The compound hypotensor preparation contains the active components comprising metoprolol 25-100 weight portions, captopril 25-100 weight portions and hydrochlorothiazide 12.5-25 weight portions. The compound hypotensor preparation has high curative effect, less side effect high performance / cost ratio, taking convenience and raised patient's compliance. It is used mainly in treating hypertension, and may be also used in treating angina pectoris, heart failure and diabetes.

The invention provides diltiazem hydrochloride sustained release tablets. The diltiazem hydrochloride sustained release tablets are prepared from 60 parts of diltiazem hydrochloride, 50-150 parts of sustained release skeleton material and 5-25 parts of lubricating agent by weight. A preparation method of the diltiazem hydrochloride sustained release tablets comprises the steps of material preparing, blending, granulating, blending, tabletting and aluminium-plastic packaging. The diltiazem hydrochloride sustained release tablets and the preparation method have the beneficial effects that the effects of dilating blood vessels, improving myocardial ischemia and reducing blood pressure are achieved by inhibiting internal flow of calcium ions towards coronary vessels and the surroundings of the coronary vessels or peripheral vascular smooth muscle cells; the diltiazem hydrochloride sustained release tablets have the advantages of good medicine stability, convenience in packaging, transportation and storage, and the like; the preparation method is simple and practicable and is suitable for industrial production.

The invention discloses an application of total alkaloids of dendrobium stem in preparation of anti-aging drugs and belongs to the technical field of biomedicine. According to the application, total alkaloids of dendrobium stem are extracted and the content is measured. Through the caenorhabditis elegans anti-aging pharmacodynamics experiment and galactose-caused influence on an aging mouse modeland SAMP8 mouse brain aging protection and mechanism study, it is proved that the total alkaloids of dendrobium stem can improve the learning and memory declining of SAMP8 mice, enhance exercise tolerance, attenuate brain atrophy in SAMP8 mice and reduce the neuronal loss. The results of the experiment are similar to those of the anti-aging drug metformin. The total alkaloids of dendrobium stem have anti-aging effects and the alkaloid action mechanism is related to up-regulation of anti-aging protein Klotho expression, reduction of A beta aggregation and induction of autophagy activity. The experiment results fully prove the anti-aging effects of the total alkaloids of dendrobium stem in anti-aging drugs.

The invention provides a nitric oxide donor traditional Chinese medicine compound preparation. The preparation comprises active raw materials and pharmaceutical acceptable auxiliary materials, whereinthe active raw materials comprise raw materials in parts by mass as follows: 50-100 parts of a first nitric oxide donor plant, 10-30 parts of a second nitric oxide donor plant, 5-20 parts of radix pseudostellariae, 5-20 parts of roasted rhizoma atractylodis macrocephalae, 5-20 parts of rosewood and 1-10 parts of leeches; and the content of nitric oxide donors in the first nitric oxide donor plantis larger than 1500 mg / kg and smaller than or equal to 3500 mg / kg, and the content of nitric oxide donors in the second nitric oxide donor plant is larger than or equal to 1000 mg / kg and smaller thanor equal to 1500 mg / kg. The nitric oxide donor traditional Chinese medicine compound preparation can be used for preventing or treating cardiovascular and cerebrovascular diseases. The invention provides a preparation method and application of the nitric oxide donor traditional Chinese medicine compound preparation. The preparation method is simple, feasible and easy to implement.

The invention provides methods for treating various indications and diseases in a patient in need thereof, wherein the patient has a C825T polymorphism in the G protein beta3 subunit (GNB3), comprising administering to the patient (i) at least one antioxidant compound or a pharmaceutically acceptable salt thereof; (ii) at least one nitric oxide enhancing compound; and (iii) optionally the best current therapy for the treatment of cardiovascular diseases. In one embodiment the antioxidant is a hydralazine compound or a pharmaceutically acceptable salt thereof and the nitric oxide enhancing compound is isosorbide dinitrate and / or isosorbide mononitrate.

The invention pertains to the field of traditional Chinese medicine and relates to a pharmaceutical composition for improving the function of skeletal muscle and treating heart failure simultaneously and a preparation method thereof. The pharmaceutical composition aims at the pathogenesis of deficient and weak yang and qi of heart and kidney, fluid retention and blood stagnation of the heart failure and adopts the traditional Chinese medicines of raw membranous milkvetch root, prepared common monkshood daughter root, largehead atractylodes rhizome, white paeony root, Indian buead, common burreed rhizome, zedoary, pepperweed seed, plantain seed, dwarf lilyturf tuber and a pharmaceutically acceptable carrier for preparation. The pharmaceutical composition has the effects of warming yang andqi of heart and kidney, eliminating pathogens from lung and inducing diuresis, the clinical and animal tests prove that the pharmaceutical composition can effectively improve the retention of sodium and water of the patients with the heart failure, liver congestion and even liver cirrhosis due to the congestion; at the same time, the pharmaceutical composition has significant protective effect ofthe damaged function of the skeletal muscle during the heart failure. The pharmaceutical composition is applicable to the patients with the heart failure and the different degrees of fluid retention.The pharmaceutical composition can improve the quality of lives of the patients with the chronic heart failure, further improve the exercise tolerance, increase the 6-minute walking distance and improve the function of the skeletal muscle during the heart failure.

The invention relates to a traditional Chinese medicine cough-asthma patch. The patch is prepared from the following raw materials in parts by weight of 15-18 g of folium mori harvested after frost descent, 25-30 g of semen brassicae, 25-30 g of herba ephedrae, 15-20 g of herba asari, 15-20 g of radix kansui, 15-20 g of unprocessed radix aconiti, 15-20 g of unprocessed radix aconiti kusnezoffii, 15-20 g of radix angelicae, 25-30 g of folium artemisiae argyi, 15-20 g of fructus gleditsiae, 15-20 g of black pepper, 500-600 g of a hot melt adhesive and 5-7 g of vanillyl butyl ether. The traditional Chinese medicine patch has the effects of improving clinical symptoms such as cough, phlegm and asthma, improving exercise tolerance, improving life quality and reducing annual acute attack times,and is particularly suitable for patients in a chronic obstructive pulmonary disease stable period and an asthma relieving period.

The invention discloses a preparation method of a cod-derived functional low-bitter oligopeptide. The steps are as follows: (1) pretreatment: after removing the skin and bones of the cod, wash it with distilled water, and squeeze out the water to obtain the cod meat for use; (2) ) homogenization: the cod fish meat obtained in step (1) is carried out primary homogenization treatment, after the fish meat after the initial homogenization is mixed with distilled water, carry out secondary homogenization to obtain cod fish minced meat; (3) enzymolysis: to step (2) ) in the cod minced meat obtained, firstly add bromelain to carry out preliminary enzymolysis, then de-enzyme, then add flavor protease to carry out two-step enzymolysis, de-enzyme; (4) centrifugal: the enzymolysis product of step (3) is at 7000-8000rpm Centrifuge for 20-30min; (5) spray drying: take the supernatant after centrifugation in step (4) and spray dry to obtain the finished product. The preparation method of the invention is simple, the preparation conditions are mild and easy to realize, and the oligopeptide prepared by the invention has low bitterness, high utilization rate, good flavor and good anti-exercise fatigue effect.

The present invention provides methods of treating and preventing mortality associated with heart failure in an African American patient with hypertension and improving oxygen consumption, quality of life and exercise tolerance by administering a therapeutically effective amount of at least one hydralazine compound and at least one of isosorbide dinitrate and isosorbide mononitrate, and, optionally, one or more compounds, such as, for example, a digitalis, a diuretic compound, or a compound used to treat cardiovascular diseases. In the present invention, the hydralazine compound is preferably hydralazine or a pharmaceutically acceptable salt thereof. Preferred methods of the invention comprise administering hydralazine or a pharmaceutically acceptable salt thereof and isosorbide dinitrate.

Provided herein are methods for treating pulmonary hypertension. The methods include administering to a subject in need thereof an effective amount of a vasodilator, wherein the vasodilator is administered to the subject via inhalation pro re nata using a portable inhaler. In some embodiments, the vasodilator is a PDE5 inhibitor. Pharmaceutical compositions for pro re nata administration of vasodilators are also described.

The invention discloses a pet health food formula for enhancing heart vitality and a preparation method thereof. The formula consists of the following components: astragalus membranaceus, ginseng, lucid ganoderma, honey-fried licorice roots, salviae miltiorrhizae, metoprolol and trimetazidine. The preparation method comprises the following steps: 1) cleaning; 2) crushing; 3) decocting; and 4) mixing. Compared with the prior art, the formula has the advantages that: the formula is simple, convenient to prepare and capable of increasing myocardial contractility of pets, reducing myocardial oxygen consumption of the pets and solving the problems of weakness and shortness of breath of the pets, so that exercise tolerance is improved, and disease resistance of the pets is enhanced. The formulahas good market popularization values.

The invention discloses application of a medicine in preparation of drugs for reducing the muscle toxicity of statins. Experimental results show that a heart-nourishing tablet can reduce statins related skeletal muscle injury and improve exercise capacity by enhancing mitochondrial activity, improving oxidative stress and inhibiting myolysis of ApoE- / -mice fed with high fat in exercise training, and the effect is remarkable.

Hypertension is recognized by the medical community at home and abroad as the "most ferocious killer" that threatens the human life, the mortality rate of hypertension is higher than that of any otherdisease, and hypertension seriously affects the human health. Atenolol tablets are administered twice per day, and the blood concentration fluctuates greatly, thereby being necessary to prepare the atenolol tablets into a slow-release preparation. The invention relates to an atenolol slow-release drop pill capable of quickly taking effect and slowly releasing drugs and used for treating hypertension and angina, performing maintenance treatment of myocardial infarction and treating arrhythmia, hyperthyroidism and the like, and a preparation method of the atenolol slow-release drop pill. In order to make up for the deficiencies of the prior art, the invention provides an atenolol slow-release drop pill preparation. The atenolol slow-release drop pill provided by the invention is characterized in that a hydrophobic skeleton capable of slowly releasing drugs and Tween-80 with a solubilizing effect are added on the basis of the existing drop pill technology, the deficiencies of the prior art are effectively overcome, and the atenolol slow-release drop pill has the advantages of uniform drug dispersion, sufficient drug release, long drug release time, reduced patient medication frequency and high bioavailability.